Halozyme Therapeutics Inc's SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares
Michael Labarre, SVP, Chief Technical Officer of Halozyme Therapeutics Inc (NASDAQ:HALO), has sold 20,000 shares of the company on January 17, 2024, according to a recent SEC Filing. Over the past year, the insider has sold a total of 145,862 shares and has not made any purchases of the stock.
Halozyme Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company's proprietary enzyme technology is used in a range of clinical and preclinical products for the treatment of cancer and other diseases.
The insider transaction history at Halozyme Therapeutics Inc reveals a pattern of 23 insider sells and no insider buys over the past year.
On the date of the insider's recent transaction, shares of Halozyme Therapeutics Inc were trading at $36, resulting in a market capitalization of $4.614 billion. The price-earnings ratio of the stock stands at 18.58, which is below both the industry median of 31.03 and the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio, based on a trading price of $36 and a GuruFocus Value of $85.61, is 0.42. This indicates that Halozyme Therapeutics Inc is significantly undervalued according to its GF Value.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
